A novel synthetic compound that interrupts androgen receptor signaling in human prostate cancer cells

Molecular Cancer Therapeutics

Volumn 6, Issue 7, 2007, Pages 2057-2064

  Lu, Shan ^a,a   Wang, Amy ^a   Dong, Zhongyun ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 6 AMINO 2 [2 (4 TERT BUTYL PHENOXY) ETHYLSULFONYL] 1H PYRIMIDINE 4 ONE; ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; BICALUTAMIDE; FLUTAMIDE; LUCIFERASE; NILUTAMIDE; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL; CARBOXY TERMINAL SEQUENCE; CELL GROWTH; CELL STIMULATION; CELL STRAIN LNCAP; CONTROLLED STUDY; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MALE; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROSTATE CANCER; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STAINING; WESTERN BLOTTING;

ANDROGENS; ANILIDES; ANTINEOPLASTIC AGENTS; CELL PROLIFERATION; DIHYDROTESTOSTERONE; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; FLUTAMIDE; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HUMANS; IMIDAZOLIDINES; MALE; NITRILES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TOSYL COMPOUNDS; TRANSCRIPTION, GENETIC;

EID: 34447306625     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0735     Document Type: Article

References (27)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Crawford ED. Challenges in the management of prostate cancer. Br J Urol 1992;70 Suppl 1:33-8.
3. Miyamoto H, Rahman MM, Chang C. Molecular basis for the antiandrogen withdrawal syndrome. J Cell Biochem 2004;91:3-12.
4. Gelmann EP. Molecular biology of the androgen receptor. J Clin Oncol 2002;20:3001-15.
5. Culig Z, Klocker H, Bartsch G, Hobisch A. Androgen receptors in prostate cancer. Endocr Relat Cancer 2002;9:155-70.
6. Prescott J, Coetzee GA. Molecular chaperones throughout the life cycle of the androgen receptor. Cancer Lett 2006;231:12-9.
7. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004;25:276-308.
8. Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004;10:33-9.
9. Isaacs JT, Isaacs WB. Androgen receptor outwits prostate cancer drugs. Nat Med 2004;10:26-7.
10. Balk SP, Ko YJ, Bubley GJ. Biology of prostate-specific antigen. J Clin Oncol 2003;21:383-91.
11. Lilja H. Biology of prostate-specific antigen. Urology 2003;62:27-33.
12. Horoszewicz JS, Leong SS, Kawinski E, et al. LNCaP model of human prostatic carcinoma. Cancer Res 1983;43:1809-18.
13. van Bokhoven A, Varella-Garcia M, Korch C, et al. Molecular characterization of human prostate carcinoma cell lines. Prostate 2003;57:205-25.
14. Sramkoski RM, Pretlow TG II, Giaconia JM, et al. A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell Dev Biol Anim 1999;35:403-9.
15. Klein KA, Reiter RE, Redula J, et al. Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat Med 1997;3:402-8.
16. Dong Z, Liu Y, Lu S, et al. Vav3 oncogene is overexpressed and regulates cell growth and androgen receptor activity in human prostate cancer. Mol Endocrinol 2006;20:2315-25.
17. Lu S, Dong Z. Characterization of TGF-β-regulated interleukin-8 expression in human prostate cancer cells. Prostate 2006;66:996-1004.
18. Langley E, Zhou ZX , Wilson EM. Evidence for an anti-parallel orientation of the ligand-activated human androgen receptor dimer. J Biol Chem 1995;270:29983-90.
19. 2-/carboxylterminal interactions in androgen receptor dimerization revealed by mutations that cause androgen insensitivity. J Biol Chem 1998;273:92-101.
20. He B, Wilson EM. The NH(2)-terminal and carboxyl-terminal interaction in the human androgen receptor. Mol Genet Metab 2002;75:293-8.
21. Zhang F, Lee J, Lu S, Pettaway CA, Dong Z. Blockade of transforming growth factor-β signaling suppresses progression of androgen-independent human prostate cancer in nude mice. Clin Cancer Res 2005;11:4512-20.
22. Kemppainen JA, Langley E, Wong CI, et al. Distinguishing androgen receptor agonists and antagonists: distinct mechanisms of activation by medroxyprogesterone acetate and dihydrotestosterone. Mol Endocrinol 1999;13:440-54.
23. Wong C, Kelce WR, Sar M, Wilson EM. Androgen receptor antagonist versus agonist activities of the fungicide vinclozolin relative to hydroxyflutamide. J Biol Chem 1995;270:19998-20003.
24. Hara T, Miyazaki J, Araki H, et al. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res 2003;63:149-53.
25. Jiang C, Lee HJ, Li GX, et al. Potent antiandrogen and androgen receptor activities of an Angelica gigas-containing herbal formulation: identification of decursin as a novel and active compound with implications for prevention and treatment of prostate cancer. Cancer Res 2006;66:453-63.
26. Koochekpour S, Lee TJ, Wang R, et al. Prosaposin up-regulates AR and PSA expression and activity in prostate cancer cells (LNCaP). Prostate 2007;67:178-89.
27. 2- and COOH-terminal interaction. J Biol Chem 2002;277:25631-9.